BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34085325)

  • 1. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
    Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H
    Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
    Herr HW; Toner GC; Geller NL; Bosl GJ
    Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
    Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
    J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
    Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
    J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
    Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
    Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
    Herr HW
    Br J Urol; 1997 Oct; 80(4):653-7. PubMed ID: 9352708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
    Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
    J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.
    Nestler T; Paffenholz P; Pfister D; Schoch J; Nini A; Hiester A; Albers P; Heidenreich A
    J Urol; 2024 Mar; 211(3):426-435. PubMed ID: 38085711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma.
    Clevenger JA; Foster RS; Ulbright TM
    Mod Pathol; 2009 Oct; 22(10):1361-6. PubMed ID: 19633644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
    Considine S; Heaney R; Conroy R; Thornhill JA
    Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood testis barrier revisited-Analysis of post-chemotherapy germ cell tumor orchidectomy and retroperitoneal lymph node dissection specimens.
    Gupta A; Noronha J; Bakshi G; Menon S; Pal M; Joshi A; Prabash K; Noronha V; Murthy V; Krishnattry R; Patil A; Prakash GJ
    J Surg Oncol; 2021 Mar; 123(4):1157-1163. PubMed ID: 33428791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
    Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
    Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection?
    Jacobsen NE; Beck SD; Jacobson LE; Bihrle R; Einhorn LH; Foster RS
    J Urol; 2010 Sep; 184(3):949-53. PubMed ID: 20643453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.
    Pedrosa JA; Masterson TA; Rice KR; Bihrle R; Beck SD; Foster RS
    J Urol; 2014 Jun; 191(6):1777-82. PubMed ID: 24518787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
    Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
    Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.